pI: 8.4677 |
Length (AA): 251 |
MW (Da): 27195 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
3 | 251 | 1sw0 (A) | 2 | 248 | 51.00 | 0 | 1 | 1.68 | -2.12 |
3 | 251 | 1kv5 (A) | 2 | 250 | 69.00 | 0 | 1 | 2.02 | -2.51 |
3 | 251 | 1n55 (A) | 2 | 250 | 92.00 | 0 | 1 | 2.13 | -2.49 |
3 | 251 | 5cg7 (A) | 3 | 251 | 92.00 | 0 | 1 | 2.17063 | -1.89 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_127002)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G21170 | triosephosphate isomerase |
Arabidopsis thaliana | AT3G55440 | triosephosphate isomerase |
Babesia bovis | BBOV_II001220 | triosephosphate isomerase protein, putative |
Brugia malayi | Bm1_29130 | triosephosphate isomerase |
Candida albicans | CaO19.6745 | similar to S. cerevisiae TPI1 (YDR050C) triose phosphate isomerase |
Candida albicans | CaO19.14037 | similar to S. cerevisiae TPI1 (YDR050C) triose phosphate isomerase |
Caenorhabditis elegans | CELE_Y17G7B.7 | Protein TPI-1 |
Cryptosporidium hominis | Chro.10337 | triose-phosphate isomerase |
Cryptosporidium parvum | cgd1_3040 | triosephosphate isomerase |
Chlamydia trachomatis | CT_328 | triosephosphate isomerase |
Dictyostelium discoideum | DDB_G0274471 | triose phosphate isomerase |
Drosophila melanogaster | Dmel_CG2171 | Triose phosphate isomerase |
Escherichia coli | b3919 | triosephosphate isomerase |
Echinococcus granulosus | EgrG_000416400 | triosephosphate isomerase |
Entamoeba histolytica | EHI_056480 | triosephosphate isomerase |
Echinococcus multilocularis | EmuJ_000416400 | triosephosphate isomerase |
Giardia lamblia | GL50803_93938 | Triosephosphate isomerase, cytosolic |
Homo sapiens | ENSG00000111669 | triosephosphate isomerase 1 |
Leishmania braziliensis | LbrM.20.5360 | triosephosphate isomerase |
Leishmania donovani | LdBPK_240870.1 | triosephosphate isomerase |
Leishmania infantum | LinJ.24.0870 | triosephosphate isomerase |
Leishmania major | LmjF.24.0850 | triosephosphate isomerase |
Leishmania mexicana | LmxM.24.0850 | triosephosphate isomerase |
Loa Loa (eye worm) | LOAG_09607 | triosephosphate isomerase |
Mycobacterium leprae | ML0572 | Probable triosephosphate isomerase Tpi (TIM) |
Mus musculus | ensembl-mmu:ENSMUSG00000023456 | triosephosphate isomerase 1 |
Mycobacterium tuberculosis | Rv1438 | Probable triosephosphate isomerase Tpi (TIM) |
Mycobacterium ulcerans | MUL_1830 | triosephosphate isomerase |
Neospora caninum | NCLIV_033270 | hypothetical protein |
Neospora caninum | NCLIV_046900 | hypothetical protein |
Oryza sativa | 4327400 | Os01g0841600 |
Oryza sativa | 4347691 | Os09g0535000 |
Oryza sativa | 4325211 | Os01g0147900 |
Plasmodium berghei | PBANKA_1303800 | triosephosphate isomerase, putative |
Plasmodium falciparum | PF3D7_1439900 | triosephosphate isomerase |
Plasmodium knowlesi | PKNH_1242400 | triosephosphate isomerase, putative |
Plasmodium vivax | PVX_118495 | triosephosphate isomerase, putative |
Plasmodium yoelii | PY04306 | triosephosphate isomerase |
Saccharomyces cerevisiae | YDR050C | triose-phosphate isomerase TPI1 |
Schistosoma japonicum | Sjp_0304690 | ko:K01803 triosephosphate isomerase (TIM) [EC5.3.1.1], putative |
Schistosoma mansoni | Smp_003990 | triosephosphate isomerase |
Schmidtea mediterranea | mk4.001789.01 | Triosephosphate isomerase |
Schmidtea mediterranea | mk4.034460.04 | Triosephosphate isomerase |
Schmidtea mediterranea | mk4.006707.00 | Triosephosphate isomerase |
Trypanosoma brucei gambiense | Tbg972.11.6230 | triosephosphate isomerase, putative |
Trypanosoma brucei | Tb927.11.5520 | triosephosphate isomerase |
Trypanosoma congolense | TcIL3000.11.5810 | triosephosphate isomerase, putative |
Trypanosoma cruzi | TcCLB.508647.200 | triosephosphate isomerase, putative |
Toxoplasma gondii | TGME49_225930 | triose-phosphate isomerase TPI-I |
Toxoplasma gondii | TGME49_233500 | triose-phosphate isomerase TPI-II |
Treponema pallidum | TP0537 | triosephosphate isomerase |
Theileria parva | TP04_0464 | triosephosphate isomerase, putative |
Trichomonas vaginalis | TVAG_497370 | triosephosphate isomerase, putative |
Trichomonas vaginalis | TVAG_096350 | triosephosphate isomerase, putative |
Wolbachia endosymbiont of Brugia malayi | Wbm0408 | triosephosphate isomerase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.02.3210 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.02.3210 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.02.3210 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb11.02.3210 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
b3919 | Escherichia coli | non-essential | goodall |
YDR050C | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_1303800 | Plasmodium berghei | Essential | plasmo |
TGME49_233500 | Toxoplasma gondii | Probably essential | sidik |
TGME49_225930 | Toxoplasma gondii | Probably essential | sidik |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania mexicana | 433604 557499 577907 | |
Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with TIM inhibitors leads to reduced enzyme activity in vitro; . | References: | 9654066 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania mexicana | No drug identifiers listed for this gene. | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 53357-04-3. chemical inhibition with TIM inhibitors leads to reduced enzyme activity in vitro; . | References: | 16489748 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.8
Compound | Source | Reference |
---|---|---|
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References |
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Oryctolagus cuniculus | Triosephosphate isomerase | Compounds | References |
Homo sapiens | triosephosphate isomerase 1 | Compounds | References |
Trypanosoma cruzi | triosephosphate isomerase, putative | Compounds | References |
Target | Type | Source | Notes |
---|---|---|---|
LmjF.24.0850 | cloned gene | BRENDA | A gene with this EC number or name or sequence has been cloned from Leishmania mexicana ( 1 ) |
16 literature references were collected for this gene.